Phase i clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

British Journal of Cancer

Volumn 108, Issue 6, 2013, Pages 1260-1266

  Yoshimura, K ^a   Minami, T ^a   Nozawa, M ^a   Uemura, H ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 1 1084 PEPTIDE; VASCULOTROPIN RECEPTOR 1 770 PEPTIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN REDNESS; TREATMENT OUTCOME; VACCINATION; X RAY;

ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; VACCINES, SUBUNIT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84876420644     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.90     Document Type: Article

References (29)

1. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293-300.
2. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
3. Finn OJ, Lotze MT (2001) A decade in the life of tumor immunology. Clin Cancer Res 7: 759-760.
4. Fisk B, Blevins TL, Wharton J, Ioannides CG (1995) Identification of an immunodominant peptide of HER2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes line. J Exp Med 181: 2109-2117.
5. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A simple culture protocol to detect peptide-specific otoxic T lymphocyte precursors in circulation. Cancer Immunol Immunother 51: 219-228.
6. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi T, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H (2007) WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530.
7. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vitro tumor rejection. Proc Natl Acad Sci USA 91: 6458-6462.
8. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352.
9. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat lmmunol 3: 999-1005.
10. Kono K, Iimura H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three-peptides derived from novel cancer-testis antigens. J Transl Med 10: 141.
11. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ (2002) Active immunization against the vascular endothelial growth factor receptor flk 1 inhibits tumor angiogenesis and metastasis. J Exp Med 195: 1575-1584.
12. Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Itoh K (2002) Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 99: 409-417.
13. Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa R, Takeda K, Yoshida K, Tsunoda T, Nakamura Y, Mori M, Doki Y (2012) Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol; e-pub ahead of print 25 July 2012; doi:10.3892/ijo.2012.1573.
14. Miyazawa M, Ohsawa R, Tsunoda T, Hirano S, Kawai M, Tani M, Nakanura Y, Yamaue H (2010) Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101: 433-439.
15. Okuno K, Sugiura F, Hida JI, Tokoro T, Ishimaru E, Sukegawa Y, Ueda K (2011) Phase I clinical trial of a novel peptide vacccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med 2: 73-79.
16. Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey A, Dalgleish A, Johnston C, Banks RE, Selby PJ (2008) An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 44: 216-223.
17. Ramanathan RK, Lee KM, Mckolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetsvhel M, Finn OF (2005) Phase I study of a MUC1vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54: 254-264.
18. Rini BI, Rathmell WK, Godley P (2008) Renal cell carcinoma. Curr Opin Oncol 20: 300-306.
19. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loflus D, Appella E, Rosenberg SA (1996) A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185-1192.
20. Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW, Schmidt J (2005) Control of T cellmediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 11: 498-504.
21. Schrader AJ, Varga Z, Hegele A, Ofoertner S, Olbert P, Hofmann R (2006) Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 132: 137-149.
22. Shibuya M (1995) Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67: 281-316.
23. Shimizu K, Uemura H, Yoshikawa M, Yoshida K, Hirao Y, Iwashima K, Saga S, Yoshikawa K (2003) Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol Rep 10: 1307-1311.
24. Slingluff Jr. CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Enqelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ros WG (2001) Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7: 3012-3024.
25. Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matsuoka K, Kanayama H (2007) Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 98: 1965-1968.
26. Suzuki N, Maeda Y, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M, Itoh K (2002) Detection of peptide-specific cytotoxic T lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 98: 45-50.
27. Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K, Itoh K (2006) A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12: 1768-1775.
28. von Mehren M (2005) Colorectal cancer vaccines: what we know and what we don't know. Semin Oncol 32: 76-84.
29. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18: 1254-1261.